Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | VNN1 | O95497 | 7/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29797818 | 0.83 | PDK2 (0.47) | PDK2VNN1PARP1ELANENTRK1 | |
| SCHEMBL31369352 | 0.77 | LMNA (0.50) | ALDH1A1 | |
| SCHEMBL29797687 | 0.75 | PDK2 (0.46) | PDK2VNN1PARP1ADRA1AMCHR1 | |
| SCHEMBL29798021 | 0.73 | PDK2 (0.47) | PDK2VNN1PARP1ELANENTRK1 | |
| SCHEMBL26616264 | 0.67 | VNN1 (0.53) | PDK2VNN1 | |
| SCHEMBL26615294 | 0.67 | VNN1 (0.53) | PDK2VNN1 | |
| SCHEMBL22031923 | 0.66 | VNN1 (0.68) | PDK2VNN1 | |
| SCHEMBL21989905 | 0.66 | VNN1 (0.68) | PDK2VNN1 | |
| SCHEMBL22031934 | 0.66 | VNN1 (0.56) | PDK2VNN1PARP1 | |
| SCHEMBL29658661 | 0.66 | VNN1 (0.68) | PDK2VNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042850-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | ATHOS THERAPEUTICS INC (US) | 2025-02-06 | — | — | US | disclosed |
| WO-2022159980-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | ATHOS THERAPEUTICS, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042850-A1 | PHARMACEUTICAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PTGES, PTGIS, HPGDS | PDK2 237/4885VNN1 1583/4885PARP1 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.